Orthocell's (ASX:OCC) revenue climbed 46% to AU$2.2 million in the three months to December 2024 from AU$1.5 million in the year-earlier period, according to a Wednesday filing with the Australian bourse.
Revenue was up 9% from AU$2 million in the three months to September 2024, marking a third consecutive quarter of record revenue.
The regenerative medicine company attributed the increase to growth in existing markets for its Striate and Remplir products, per the filing. It anticipates the US Food and Drug Administration's approval of Remplir by March or April, enabling it to unlock a $1.6 billion nerve repair market.
Orthocell's shares rose past 5% in recent Wednesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。